MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Malignant pleural mesothelioma – Pleural cavity irradiation after decortication with helical tomotherapy

Reports of Practical Oncology and Radiotherapy 2017 September [Epub 2017 August 11] [Link]

Harrabi SB, Koerber SA, Adeberg S, Katayama S, Herfarth K, Debus J, Sterzing F

Abstract

BACKGROUND:
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease that poses a treatment challenge in spite of recent technical developments. The aim of this retrospective analysis is to assess the feasibility of administering intensity-modulated radiotherapy (IMRT) to the pleural cavity using helical tomotherapy in patients who had undergone pleurectomy/decortication (P/D) and also the resulting toxicity levels.
PATIENTS AND METHODS:
Ten patients who had MPM and had undergone P/D were treated with pleural cavity irradiation that included a median dose of 52.2 Gy using helical tomotherapy. The median age of the patients was 53 years (31-74). In addition to clinical and diagnostic findings from regular follow-up examinations, we evaluated the dose distribution for other organs at risk to assess treatment in relation to toxicity, with special regard for the underlying intact lung.
RESULTS:
The mean lung dose on the treatment site was 32.8 Gy (±6.8). The V20 Gy was 71.7% (±17.2). No treatment-related toxicity that exceeded grade III according to common toxicity criteria (CTC) was observed. Median progression-free survival (PFS) was 13 months with a median overall survival (OAS) of 19 months.
CONCLUSION:
The findings of this analysis provide data indicating that sparing the underlying lung in patients with MPM after P/D is not only feasible with helical tomotherapy, but that this treatment also causes reasonably few side effects.

Both comments and trackbacks are currently closed.